Tectonic Therapeutic

Tectonic Therapeutic is a clinical-stage biotechnology company discovering and developing therapeutic proteins and antibodies that modulate G-protein-coupled receptors (GPCRs), focused on cardiovascular and vascular disease. Its lead program, TX45, is a long-acting Fc-relaxin fusion protein in the pivotal APEX Phase 2 trial for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF); a second program, TX2100, is in Phase 1a for hereditary hemorrhagic telangiectasia (HHT). The company reported $227.1M in cash at June 30, 2026, projected to fund operations into Q1 2029.